Skip to main content

Atidarsagene autotemcel Disease Interactions

There are 4 disease interactions with atidarsagene autotemcel.

Moderate

Atidarsagene autotemcel (applies to atidarsagene autotemcel) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Atidarsagene autotemcel has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment prior to treatment to ensure that hematopoietic stem cell transplantation is appropriate.

References

  1. (2024) "Product Information. Lenmeldy (atidarsagene autotemcel)." Orchard Therapeutics
Moderate

Atidarsagene autotemcel (applies to atidarsagene autotemcel) HIV and other infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, HIV Infection

Atidarsagene autotemcel has not been studied in patients with HIV-1/2, human T-lymphotrophic virus 1 and 2 (HTLV-1/2), HBV, HCV, or mycoplasma infection. Patients should be screened for these infectious disease before collection of cells for the manufacturing of atidarsagene autotemcel. Patients should not take prophylactic HIV anti-retroviral medications for at least 1 month prior to mobilization, or for the expected duration of time needed for the elimination of the medications. If a patient requires anti-retrovirals for HIV prophylaxis, initiation of atidarsagene autotemcel should be delayed until confirmation of a negative test for HIV.

References

  1. (2024) "Product Information. Lenmeldy (atidarsagene autotemcel)." Orchard Therapeutics
Moderate

Atidarsagene autotemcel (applies to atidarsagene autotemcel) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Atidarsagene autotemcel has not been studied in patients with renal impairment. Patients should be assessed for renal impairment prior to treatment with atidarsagene autotemcel to ensure that hematopoietic stem cell transplantation is appropriate.

References

  1. (2024) "Product Information. Lenmeldy (atidarsagene autotemcel)." Orchard Therapeutics
Moderate

Atidarsagene autotemcel (applies to atidarsagene autotemcel) thrombosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder

Thrombosis, thromboembolic events, and veno-occlusive disease have occurred in patients treated with atidarsagene autotemcel. Some patients received anti-thrombotic prophylaxis in clinical trials. Evaluate patients for preexisting risk factors for thrombosis prior to and after infusion of atidarsagene autotemcel. Consider prophylaxis with anti-thrombotic agents based on risk factors and best clinical practice.

References

  1. (2024) "Product Information. Lenmeldy (atidarsagene autotemcel)." Orchard Therapeutics

Atidarsagene autotemcel drug interactions

There are 122 drug interactions with atidarsagene autotemcel.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer